Binyamin O, Nitzan K, Frid K, Ungar Y, Rosenmann H, Gabizon R Brain targeting of 9c,11t-Conjugated Linoleic Acid, a natural calpain inhibitor, preserves memory and reduces Aß and P25 accumulation in 5XFAD mice. Sci Rep. 2019 Dec 5;9(1):18437. doi: 10.1038/s41598-019-54971-9. Erratum in: Sci Rep. 2020 Jan 23;10(1):1320.
Eshuis SA, Maguire RP, Leenders KL, Jonkman S, Jager PL Comparison of FP-CIT SPECT with F-DOPA PET in patients with de novo and advanced Parkinson's disease. Eur J Nucl Med Mol Imaging. 2006 Feb;33(2):200-9. Epub 2005 Oct 15.
Keller G, Binyamin O, Frid K, Saada A, Gabizon R Mitochondrial dysfunction in preclinical genetic prion disease: A target for preventive treatment? Neurobiol Dis. 2019 Apr;124:57-66. doi: 10.1016/j.nbd.2018.11.003. Epub 2018 Nov 10.
Kumakura Y, Gjedde A, Danielsen EH, Christensen S, Cumming P Dopamine storage capacity in caudate and putamen of patients with early Parkinson's disease: correlation with asymmetry of motor symptoms. J Cereb Blood Flow Metab. 2006 Mar;26(3):358-70.
Pysz MA, Gambhir SS, Willmann JK Molecular imaging: current status and emerging strategies. Clin Radiol. 2010 Jul;65(7):500-16. doi: 10.1016/j.crad.2010.03.011. Review.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
